Business Context and Reporting Period
Cocrystal Pharma, Inc. filed this Form 8-K on June 23, 2014, reporting the completion of an asset disposition and related financial transactions. The Company, a small business issuer incorporated in Delaware, previously sold its operating assets to MusclePharm Corporation ("MusclePharm") in a transaction that resulted in Cocrystal receiving MusclePharm common stock.
Key Financial Metrics and Transaction Details
- Asset Sale Proceeds: The Company sold 600,000 shares of MusclePharm common stock to non-affiliated accredited investors for a total of $5.4 million ($9.00 per share).
- Debt Repayment: From the proceeds, the Company paid $2,626,290.72 to EverBank to acquire a promissory note secured by a deed of trust on its former principal operations property.
- Remaining Holdings: The Company retains an additional 600,000 shares of MusclePharm common stock held in escrow.
- Lock-Up Waiver: MusclePharm agreed to waive Lock-Up/Leak-Out requirements for the 600,000 shares sold to purchasers, though a Lock-Up/Leak-Out Agreement remains in place for the purchasers limiting sales to 12.5% per calendar month for eight months if shares are sold below $14.50.
Material Changes and Operational Updates
The filing details the resolution of a property-related obligation. The Company had previously assigned its lease for the Property to MusclePharm, which triggered approval requirements from the landlord and EverBank that were not initially received. By acquiring the promissory note from EverBank, the Company became the holder of the Note and subsequently notified the landlord of its consent to the change of control. The filing references ongoing litigation filed by the landlord, described in the Form 10-Q for the three months ended March 31, 2014.
Guidance, Risks, and Contingencies
The filing does not provide forward-looking financial guidance or revenue projections. The primary risk identified is the ongoing litigation with the landlord regarding the property lease and change of control, which was previously disclosed in the Company's Form 10-Q. The transaction resolves the immediate debt obligation to EverBank but leaves the Company with significant equity exposure in MusclePharm stock subject to market conditions and escrow terms.
Investor Verification Checklist
- Verify the status of the litigation with the landlord referenced in the Form 10-Q for the period ended March 31, 2014.
- Confirm the current market value of the remaining 600,000 MusclePharm shares held in escrow.
- Review the terms of the Lock-Up/Leak-Out Agreement to understand restrictions on the new shareholders and potential market impact.
- Assess the Company's remaining cash position after the $2.6 million debt payment and the $5.4 million inflow.